CR10358A - Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos - Google Patents

Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos

Info

Publication number
CR10358A
CR10358A CR10358A CR10358A CR10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
processes
pirazinas
phosphodesterase
pirido
Prior art date
Application number
CR10358A
Other languages
English (en)
Inventor
Norbert Hofgen
Hans Stange
Barbara Langen
Rudolf Schindler
Thomas Pfeifer
Chris Rundfeldt
Ute Egerland
Original Assignee
Elbion Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Gmbh filed Critical Elbion Gmbh
Publication of CR10358A publication Critical patent/CR10358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se relaciona con pirido[3,2-e]piracinas, con procesos para prepararlas, con preparaciones farmaceuticas las cuales comprenden esos compuestos y con el uso farmaceutico de esos compuestos, los cuales son inhibidores de fosfodiesterasa 10, como compuestos activos para tratar enfermedades de mamiferos incluyendo humanos los cuales pueden ser diferenciados por el uso de compuestos de acuerdo a la invencion para inhibir la actividad de la fosfodiesterasa 10 en el sistema nervioso central.
CR10358A 2006-05-30 2008-10-10 Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos CR10358A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80924206P 2006-05-30 2006-05-30

Publications (1)

Publication Number Publication Date
CR10358A true CR10358A (es) 2009-01-07

Family

ID=38441604

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10358A CR10358A (es) 2006-05-30 2008-10-10 Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos

Country Status (21)

Country Link
US (2) US7550465B2 (es)
EP (1) EP2021342A1 (es)
JP (1) JP2009538853A (es)
KR (1) KR20090013834A (es)
CN (1) CN101454324A (es)
AR (1) AR061206A1 (es)
AU (1) AU2007267392A1 (es)
BR (1) BRPI0712132A2 (es)
CA (1) CA2651849A1 (es)
CL (1) CL2007001554A1 (es)
CR (1) CR10358A (es)
GT (1) GT200800265A (es)
IL (1) IL193740A0 (es)
MX (1) MX2008014569A (es)
NO (1) NO20085326L (es)
PE (1) PE20080711A1 (es)
RU (1) RU2008152440A (es)
SV (1) SV2009003048A (es)
TW (1) TW200817400A (es)
WO (1) WO2007137820A1 (es)
ZA (1) ZA200807517B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2671980C (en) * 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
US20090143392A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
US7875618B2 (en) * 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
WO2009135495A1 (en) * 2008-05-07 2009-11-12 H. Lundbeck A/S Method for treating cognitive deficits
US20100120762A1 (en) * 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
RU2746871C2 (ru) * 2010-07-20 2021-04-21 Сиренейк Фармасьютикалз Инк. Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
SI3135286T1 (sl) * 2010-07-20 2024-02-29 Minerva Neurosciences, Inc. Postopek uporabe derivatov cikličnega amida za zdravljenje shizofrenije in njenih simptomov
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013034761A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Pyridine compounds and uses thereof
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
SG11201402134VA (en) 2011-11-09 2014-06-27 Abbvie Deutschland Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
PE20142258A1 (es) 2012-04-25 2015-01-15 Takeda Pharmaceutical Compuesto heterociclico nitrogenado
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
US9464085B2 (en) * 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2895489B1 (en) 2012-09-17 2017-10-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
MX2015012008A (es) 2013-03-14 2016-04-15 Abbvie Deutschland Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
WO2020065583A1 (en) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
CN114524808B (zh) * 2022-02-21 2023-10-24 深圳市儿童医院 一种吡唑衍生物及其作为pde10抑制剂的用途
CN114524806B (zh) * 2022-02-22 2024-09-03 深圳市儿童医院 一种三氮唑衍生物及其作为pde10抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
CA2110942A1 (en) * 1991-06-14 1992-12-23 Pharmacia & Upjohn Company Llc Imidazo¬1,5-a|quinoxalines
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors

Also Published As

Publication number Publication date
AU2007267392A1 (en) 2007-12-06
ZA200807517B (en) 2009-06-24
AR061206A1 (es) 2008-08-13
IL193740A0 (en) 2009-05-04
US20080027064A1 (en) 2008-01-31
EP2021342A1 (en) 2009-02-11
GT200800265A (es) 2010-07-22
CL2007001554A1 (es) 2008-01-18
TW200817400A (en) 2008-04-16
NO20085326L (no) 2008-12-19
SV2009003048A (es) 2009-02-11
JP2009538853A (ja) 2009-11-12
CN101454324A (zh) 2009-06-10
WO2007137820A1 (en) 2007-12-06
PE20080711A1 (es) 2008-06-14
KR20090013834A (ko) 2009-02-05
RU2008152440A (ru) 2010-07-10
BRPI0712132A2 (pt) 2012-01-17
US7550465B2 (en) 2009-06-23
US20090239874A1 (en) 2009-09-24
MX2008014569A (es) 2008-12-03
CA2651849A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
CR10358A (es) Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos
ECSP12008540A (es) PIRROL[2,3-b]PIRIDINAS Y PIRROL[2,3-b]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORES DE QUINASAS JANUS
GT201300291A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias.
CR9781A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
CO6531468A2 (es) Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
MX386924B (es) Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
CL2013001464A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras.
BR112012022650A2 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CL2008003578A1 (es) Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CL2019001669A1 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1.
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
CR8546A (es) DERIVADOS DE 1H-TIENO [2,3c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
UA110245C2 (xx) ПОХІДНІ 7-(ГЕТЕРОАРИЛАМІНО)-6,7,8,9-ТЕТРАГІДРОПІРИДО$1,2-а]ІНДОЛ-ОЦТОВОЇ КИСЛОТИ ТА ЇХ ЗАСТОСУВАННЯ ЯК МОДУЛЯТОРІВ РЕЦЕПТОРА ПРОСТАГЛАНДИНУ D2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)